| 09/22/2026 4:04 PM | Werewolf Therapeutics (1785530) Filer | Form S-4 Registration statement under Securities Act of 1933 | |
| 09/21/2026 10:11 AM | MOLL PETER (1732748) Filed by Werewolf Therapeutics (1785530) Subject | Form SCHEDULE 13G | |
| 08/21/2026 8:10 AM | Werewolf Therapeutics (1785530) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 08/21/2026 8:12 AM | Werewolf Therapeutics (1785530) Subject | Form 425 | |
| 08/20/2026 3:06 PM | Werewolf Therapeutics (1785530) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 07/31/2026 6:10 AM | Werewolf Therapeutics (1785530) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 07/31/2026 6:06 AM | Werewolf Therapeutics (1785530) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 07/08/2026 4:34 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 07/06/2026 4:18 PM | MPM BioVentures 2014, L.P. (1609492) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 07/06/2026 4:18 PM | MPM BioVentures 2014 (0) B Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 07/06/2026 4:18 PM | UBS Oncology Impact Fund L.P. (1691428) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
Get the Latest News and Ratings for HOWL and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Werewolf Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
|
| 07/06/2026 4:19 PM | MPM ASSET MANAGEMENT LLC (1263048) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 07/06/2026 4:19 PM | MPM Asset Management Investors BV2014 LLC (1609495) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 07/06/2026 4:19 PM | MPM ONCOLOGY INNOVATIONS FUND LP (1719960) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 07/02/2026 7:26 PM | RA CAPITAL MANAGEMENT, L.P. (1346824) Filed by Werewolf Therapeutics (1785530) Subject | Form SCHEDULE 13D/A | |
| 06/29/2026 6:07 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/29/2026 4:29 PM | MPM BioVentures 2014, L.P. (1609492) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/29/2026 4:29 PM | MPM BioVentures 2014 (0) B Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/29/2026 4:29 PM | UBS Oncology Impact Fund L.P. (1691428) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/29/2026 4:29 PM | MPM ASSET MANAGEMENT LLC (1263048) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/29/2026 4:30 PM | MPM Asset Management Investors BV2014 LLC (1609495) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/29/2026 4:30 PM | MPM ONCOLOGY INNOVATIONS FUND LP (1719960) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/26/2026 4:39 PM | RA CAPITAL MANAGEMENT, L.P. (1346824) Filed by Werewolf Therapeutics (1785530) Subject | Form SCHEDULE 13D/A | |
| 06/22/2026 5:59 PM | Kolchinsky Peter (1384859) Reporting RA Capital Healthcare Fund LP (1315082) Reporting RA CAPITAL MANAGEMENT, L.P. (1346824) Reporting Shah Rajeev M. (1619841) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/22/2026 6:02 PM | RA CAPITAL MANAGEMENT, L.P. (1346824) Filed by Werewolf Therapeutics (1785530) Subject | Form SCHEDULE 13D/A | |
| 06/16/2026 5:01 PM | Kolchinsky Peter (1384859) Reporting RA Capital Healthcare Fund LP (1315082) Reporting RA CAPITAL MANAGEMENT, L.P. (1346824) Reporting Shah Rajeev M. (1619841) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/15/2026 7:16 PM | RA CAPITAL MANAGEMENT, L.P. (1346824) Filed by Werewolf Therapeutics (1785530) Subject | Form SCHEDULE 13D/A | |
| 06/11/2026 7:13 PM | Kolchinsky Peter (1384859) Reporting RA Capital Healthcare Fund LP (1315082) Reporting RA CAPITAL MANAGEMENT, L.P. (1346824) Reporting Shah Rajeev M. (1619841) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/10/2026 4:20 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/08/2026 5:13 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/03/2026 5:42 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/29/2026 5:51 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/28/2026 4:02 PM | MPM ONCOLOGY INNOVATIONS FUND LP (1719960) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/28/2026 4:03 PM | MPM Asset Management Investors BV2014 LLC (1609495) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/28/2026 4:03 PM | MPM ASSET MANAGEMENT LLC (1263048) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/28/2026 4:03 PM | UBS Oncology Impact Fund L.P. (1691428) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/28/2026 4:03 PM | MPM BioVentures 2014 (0) B Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/28/2026 4:04 PM | MPM BioVentures 2014, L.P. (1609492) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/26/2026 5:18 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/20/2026 5:08 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/18/2026 4:01 PM | MPM Asset Management Investors BV2014 LLC (1609495) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
Federal Reserve Reveals Disturbing New Plan To Control Your Money (Ad) Docket No. OP-1670 is drawing attention for what it reveals about the Federal Reserve's next move. Buried on page 84 is a plan that could expand oversight of checking accounts, purchases, and money transfers across the country.
Martin D. Weiss, PhD, founder of Weiss Ratings, breaks down what this document means and why it could roll out as soon as this summer. Watch the video to learn how this plan could affect you |
| 05/18/2026 4:01 PM | MPM ASSET MANAGEMENT LLC (1263048) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/18/2026 4:02 PM | UBS Oncology Impact Fund L.P. (1691428) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/18/2026 4:02 PM | MPM BioVentures 2014 (0) B Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/18/2026 4:02 PM | MPM BioVentures 2014, L.P. (1609492) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/18/2026 4:03 PM | MPM ONCOLOGY INNOVATIONS FUND LP (1719960) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/14/2026 4:23 PM | RA CAPITAL MANAGEMENT, L.P. (1346824) Filed by Werewolf Therapeutics (1785530) Subject | Form SCHEDULE 13D/A | |
| 05/13/2026 3:06 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/12/2026 6:56 PM | MPM BioVentures 2014, L.P. (1609492) Filed by Werewolf Therapeutics (1785530) Subject | Form SCHEDULE 13D/A | |
| 05/12/2026 6:47 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/12/2026 5:26 PM | Kolchinsky Peter (1384859) Reporting RA Capital Healthcare Fund LP (1315082) Reporting RA CAPITAL MANAGEMENT, L.P. (1346824) Reporting Shah Rajeev M. (1619841) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/11/2026 3:31 PM | MPM Asset Management Investors BV2014 LLC (1609495) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/11/2026 3:32 PM | UBS Oncology Impact Fund L.P. (1691428) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/11/2026 3:32 PM | MPM BioVentures 2014 (0) B Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/11/2026 3:32 PM | MPM BioVentures 2014, L.P. (1609492) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/11/2026 3:33 PM | MPM ASSET MANAGEMENT LLC (1263048) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/11/2026 3:33 PM | MPM ONCOLOGY INNOVATIONS FUND LP (1719960) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/07/2026 5:22 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/05/2026 6:04 PM | MPM BioVentures 2014, L.P. (1609492) Filed by Werewolf Therapeutics (1785530) Subject | Form SCHEDULE 13D/A | |
| 05/04/2026 5:00 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/01/2026 3:52 PM | UBS Oncology Impact Fund L.P. (1691428) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/01/2026 3:52 PM | MPM Asset Management Investors BV2014 LLC (1609495) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/01/2026 3:51 PM | MPM ASSET MANAGEMENT LLC (1263048) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/01/2026 3:51 PM | MPM ONCOLOGY INNOVATIONS FUND LP (1719960) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/01/2026 3:51 PM | MPM BioVentures 2014, L.P. (1609492) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/01/2026 3:52 PM | MPM BioVentures 2014 (0) B Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/29/2026 6:16 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 04/29/2026 3:47 PM | MPM ONCOLOGY INNOVATIONS FUND LP (1719960) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/29/2026 3:47 PM | MPM BioVentures 2014, L.P. (1609492) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/29/2026 3:47 PM | MPM BioVentures 2014 (0) B Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/29/2026 3:48 PM | UBS Oncology Impact Fund L.P. (1691428) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/29/2026 3:48 PM | MPM Asset Management Investors BV2014 LLC (1609495) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/29/2026 3:48 PM | MPM ASSET MANAGEMENT LLC (1263048) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/27/2026 3:59 PM | MPM ONCOLOGY INNOVATIONS FUND LP (1719960) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/27/2026 4:00 PM | MPM BioVentures 2014, L.P. (1609492) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/27/2026 4:00 PM | UBS Oncology Impact Fund L.P. (1691428) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/27/2026 4:00 PM | MPM BioVentures 2014 (0) B Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/27/2026 4:01 PM | MPM Asset Management Investors BV2014 LLC (1609495) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/27/2026 4:01 PM | MPM ASSET MANAGEMENT LLC (1263048) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 03/27/2026 6:07 AM | Werewolf Therapeutics (1785530) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 03/27/2026 6:12 AM | Werewolf Therapeutics (1785530) Filer | Form 10-K Annual report pursuant to Section 13 or 15(d) | |
| 02/24/2026 4:26 PM | Werewolf Therapeutics (1785530) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 02/11/2026 2:46 PM | Longwood Fund III, L.P. (1640546) Filed by Werewolf Therapeutics (1785530) Subject | Form SCHEDULE 13G/A | |
| 02/06/2026 3:41 PM | Werewolf Therapeutics (1785530) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 01/20/2026 3:07 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/16/2026 4:36 PM | MPM BioVentures 2014, L.P. (1609492) Filed by Werewolf Therapeutics (1785530) Subject | Form SCHEDULE 13D/A | |
| 01/15/2026 4:22 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/12/2026 4:09 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/07/2026 4:12 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/06/2026 3:58 PM | MPM Asset Management Investors BV2014 LLC (1609495) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 01/06/2026 3:59 PM | MPM ASSET MANAGEMENT LLC (1263048) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
Trump's about to unleash his Midterm Weapon (Ad) Trump is turning the midterms into a referendum on American energy, pushing for more oil, more gas, and lower prices before November 3.
One small oil and gas company sits atop the largest oil and gas deposit ever found on American soil and is integrating AI technology into its wells, with margins rivaling firms valued ten times higher.
A previous stock pick from this same screening process rose more than 1,000 percent in under 12 months. Read the full pre-midterm energy stock briefing now |
| 01/06/2026 3:54 PM | MPM ONCOLOGY INNOVATIONS FUND LP (1719960) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 01/06/2026 3:54 PM | MPM BioVentures 2014, L.P. (1609492) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 01/06/2026 3:56 PM | UBS Oncology Impact Fund L.P. (1691428) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 01/06/2026 3:57 PM | MPM BioVentures 2014 (0) B Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 01/02/2026 4:32 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/29/2025 5:59 PM | MPM BioVentures 2014, L.P. (1609492) Filed by Werewolf Therapeutics (1785530) Subject | Form SCHEDULE 13D/A | |
| 12/29/2025 4:27 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/29/2025 3:45 PM | MPM ASSET MANAGEMENT LLC (1263048) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/29/2025 3:45 PM | MPM BioVentures 2014 (0) B Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |